vs
Side-by-side financial comparison of International General Insurance Holdings Ltd. (IGIC) and Bio-Techne (TECH). Click either name above to swap in a different company.
International General Insurance Holdings Ltd. is the larger business by last-quarter revenue ($403.8M vs $295.9M, roughly 1.4× Bio-Techne). International General Insurance Holdings Ltd. runs the higher net margin — 26.0% vs 12.8%, a 13.2% gap on every dollar of revenue.
China Taiping Insurance Holdings Company Limited (CTIH) formerly China Insurance International Holdings Company Limited (CIIH), is a Chinese insurance conglomerate. The company has strong Chinese Central Government background despite being incorporated in Hong Kong. It is considered as a red chip company.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
IGIC vs TECH — Head-to-Head
Income Statement — Q3 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $403.8M | $295.9M |
| Net Profit | $105.1M | $38.0M |
| Gross Margin | — | 64.6% |
| Operating Margin | — | 18.4% |
| Net Margin | 26.0% | 12.8% |
| Revenue YoY | — | -6.4% |
| Net Profit YoY | — | 68.3% |
| EPS (diluted) | $2.31 | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $295.9M | ||
| Q3 25 | $403.8M | — | ||
| Q2 25 | $261.9M | $317.0M | ||
| Q1 25 | — | $316.2M | ||
| Q4 24 | — | $297.0M | ||
| Q3 24 | $369.6M | $289.5M | ||
| Q2 24 | $265.8M | $306.1M | ||
| Q1 24 | — | $303.4M |
| Q4 25 | — | $38.0M | ||
| Q3 25 | $105.1M | — | ||
| Q2 25 | $61.4M | $-17.7M | ||
| Q1 25 | — | $22.6M | ||
| Q4 24 | — | $34.9M | ||
| Q3 24 | $-134.4M | $33.6M | ||
| Q2 24 | $70.7M | $40.6M | ||
| Q1 24 | — | $49.1M |
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 62.7% | ||
| Q1 25 | — | 67.9% | ||
| Q4 24 | — | 65.3% | ||
| Q3 24 | — | 63.2% | ||
| Q2 24 | — | 66.4% | ||
| Q1 24 | — | 67.4% |
| Q4 25 | — | 18.4% | ||
| Q3 25 | — | — | ||
| Q2 25 | 24.2% | -7.5% | ||
| Q1 25 | — | 12.2% | ||
| Q4 24 | — | 16.0% | ||
| Q3 24 | — | 13.8% | ||
| Q2 24 | -73.3% | 15.0% | ||
| Q1 24 | — | 22.1% |
| Q4 25 | — | 12.8% | ||
| Q3 25 | 26.0% | — | ||
| Q2 25 | 23.5% | -5.6% | ||
| Q1 25 | — | 7.1% | ||
| Q4 24 | — | 11.7% | ||
| Q3 24 | -36.4% | 11.6% | ||
| Q2 24 | 26.6% | 13.3% | ||
| Q1 24 | — | 16.2% |
| Q4 25 | — | $0.24 | ||
| Q3 25 | $2.31 | — | ||
| Q2 25 | $1.36 | $-0.11 | ||
| Q1 25 | — | $0.14 | ||
| Q4 24 | — | $0.22 | ||
| Q3 24 | $1.82 | $0.21 | ||
| Q2 24 | $1.55 | $0.26 | ||
| Q1 24 | — | $0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $244.7M | $172.9M |
| Total DebtLower is stronger | — | $260.0M |
| Stockholders' EquityBook value | $654.8M | $2.0B |
| Total Assets | $2.0B | $2.5B |
| Debt / EquityLower = less leverage | — | 0.13× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $172.9M | ||
| Q3 25 | $244.7M | — | ||
| Q2 25 | $164.8M | $162.2M | ||
| Q1 25 | — | $140.7M | ||
| Q4 24 | — | $177.5M | ||
| Q3 24 | $219.2M | $187.5M | ||
| Q2 24 | $237.3M | $152.9M | ||
| Q1 24 | — | $145.3M |
| Q4 25 | — | $260.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $346.0M | ||
| Q1 25 | — | $330.0M | ||
| Q4 24 | — | $300.0M | ||
| Q3 24 | — | $300.0M | ||
| Q2 24 | — | $319.0M | ||
| Q1 24 | — | $389.0M |
| Q4 25 | — | $2.0B | ||
| Q3 25 | $654.8M | — | ||
| Q2 25 | $662.3M | $1.9B | ||
| Q1 25 | — | $2.0B | ||
| Q4 24 | — | $2.1B | ||
| Q3 24 | $540.5M | $2.1B | ||
| Q2 24 | $588.2M | $2.1B | ||
| Q1 24 | — | $2.0B |
| Q4 25 | — | $2.5B | ||
| Q3 25 | $2.0B | — | ||
| Q2 25 | $2.1B | $2.6B | ||
| Q1 25 | — | $2.6B | ||
| Q4 24 | — | $2.7B | ||
| Q3 24 | $1.8B | $2.7B | ||
| Q2 24 | $2.0B | $2.7B | ||
| Q1 24 | — | $2.7B |
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.15× | ||
| Q1 24 | — | 0.19× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IGIC
Segment breakdown not available.
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
